Blood Cell Profiles as Predictors of Treatment Response and Outcomes in Neoadjuvant Immunotherapy with Chemotherapy for Esophageal Squamous Cell Carcinoma - Takeaways - MDSpire

Blood Cell Profiles as Predictors of Treatment Response and Outcomes in Neoadjuvant Immunotherapy with Chemotherapy for Esophageal Squamous Cell Carcinoma

  • By

  • Xingqiang Ran

  • Chengcheng Zhang

  • Li Zheng

  • Tao Luo

  • Binwen Xu

  • Yue Zhang

  • Liwen Zhang

  • Bo Yang

  • Maoyong Fu

  • December 11, 2025

  • 0 min

Share

  • 1

    Esophageal cancer is a leading cause of cancer-related deaths, with squamous cell carcinoma being the predominant subtype in China.

  • 2

    Neoadjuvant immunotherapy combined with chemotherapy is now the standard treatment for locally advanced esophageal cancer.

  • 3

    This study investigates the predictive value of peripheral blood cell profiles for treatment response in esophageal squamous cell carcinoma.

  • 4

    A total of 91 patients with clinical stage II–IVA esophageal squamous cell carcinoma were included in the study.

  • 5

    Postoperative pathological complete response is defined as the absence of viable tumor cells in the resected specimen.

Original Source(s)

Blood Cell Profiles as Predictors of Treatment Response and Outcomes in Neoadjuvant Immunotherapy with Chemotherapy for Esophageal Squamous Cell Carcinoma

  • by Xingqiang Ran, Chengcheng Zhang, Li Zheng, Tao Luo, Binwen Xu, Yue Zhang, Liwen Zhang, Bo Yang, Maoyong Fu

  • December 11, 2025

Related Content

A model combining deep learning and ensemble learning for melanoma recognition via dermoscopy

Skin cancer risk in alopecia areata: a systematic review and meta-analysis

Dana-Farber Research News 05.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from April 16 - 30.

  • by

  • May 15, 2026

  • 21 min